Vor Biopharma VOR Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vor Biopharma's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vor Biopharma's operating lease liabilities (total)?
- Vor Biopharma (VOR) reported operating lease liabilities (total) of $2.94M in Q1 2026.
- How has Vor Biopharma's operating lease liabilities (total) changed year-over-year?
- Vor Biopharma's operating lease liabilities (total) decreased by 90.5% year-over-year, from $30.78M to $2.94M.
- What is the long-term trend for Vor Biopharma's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Vor Biopharma's operating lease liabilities (total) has grown at a -30.3% compound annual growth rate (CAGR), from $18.29M to $3M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.